about
The restorative role of annexin A1 at the blood-brain barrier.A novel Alzheimer's disease drug candidate targeting inflammation and fatty acid metabolism.NETosis in Alzheimer's Disease.Electronegative Low-Density Lipoprotein L5 Impairs Viability and NGF-Induced Neuronal Differentiation of PC12 Cells via LOX-1.Inhibition of glial hemichannels by boldine treatment reduces neuronal suffering in a murine model of Alzheimer's disease.The Relationship between Markers of Inflammation and Degeneration in the Central Nervous System and the Blood-Brain Barrier Impairment in Alzheimer's Disease.Astrocytes contribute to Aβ-induced blood-brain barrier damage through activation of endothelial MMP9.Luteolin Inhibits Fibrillary β-Amyloid1-40-Induced Inflammation in a Human Blood-Brain Barrier Model by Suppressing the p38 MAPK-Mediated NF-κB Signaling Pathways.Rho-associated protein kinases as therapeutic targets for both vascular and parenchymal pathologies in Alzheimer's disease.The role of melatonin in the onset and progression of type 3 diabetes.Blood-Brain Barrier Dysfunction and the Pathogenesis of Alzheimer's Disease.Rebalancing β-Amyloid-Induced Decrease of ATP Level by Amorphous Nano/Micro Polyphosphate: Suppression of the Neurotoxic Effect of Amyloid β-Protein Fragment 25-35.Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease.Alzheimer’s Disease, Brain Injury, and C.N.S. Nanotherapy in Humans: Sonoporation Augmenting Drug Targeting.MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies.Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function.β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View.The blood brain barrier: Insights from development and ageing.A transgenic zebrafish model for the in vivo study of the blood and choroid plexus brain barriers using claudin 5.Focused ultrasound as a novel strategy for Alzheimer disease therapeutics.Counteracting the effects of TNF receptor-1 has therapeutic potential in Alzheimer's disease.Impact of Nitric Oxide Bioavailability on the Progressive Cerebral and Peripheral Circulatory Impairments During Aging and Alzheimer's Disease.Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?Age-related Beta-synuclein Alters the p53/Mdm2 Pathway and Induces the Apoptosis of Brain Microvascular Endothelial Cells In Vitro.The Dose-Dependent Effects of Vascular Risk Factors on Dynamic Compensatory Neural Processes in Mild Cognitive Impairment.Targeting inflammatory monocytes in sepsis-associated encephalopathy and long-term cognitive impairment.Longitudinal chemokine profile expression in a blood-brain barrier model from Alzheimer transgenic versus wild-type mice.Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer's Disease and Reconstruction of Relevant Biological MechanismsIs Beta-Amyloid Accumulation a Cause or Consequence of Alzheimer's Disease?Blood-Cerebrospinal Fluid Barrier Gradients in Mild Cognitive Impairment and Alzheimer's Disease: Relationship to Inflammatory Cytokines and Chemokines
P2860
Q27687514-D29FE82A-9D87-4149-91B0-2038E02F8C1CQ33909566-EA8D1378-3611-4B1C-86CB-DA19A0DBE0DCQ37675611-884E04CF-67BD-4D9F-B53D-0DC379DF4441Q38628959-D66E9E06-4D18-48C3-8B34-3CC0A43336DBQ38658312-3B182D96-C0E3-4B6C-A09B-56ADB8E35B67Q38683919-C2DBE929-2875-49E3-80AA-EFA1FC57A58EQ38794680-11129786-65CE-4A92-B128-96356243A5F3Q39159131-4BDBA50F-E75B-48C2-AFAD-90C26385A919Q39444002-21529694-51A6-477A-A7F3-BF88514118CCQ41206619-809F2580-9D9E-4853-84E0-FB4331567C9CQ41660607-6DA2812F-8742-4F64-94EA-918C6460A481Q43227037-E44DF944-40D3-4656-A679-ABECC8BFAC4CQ47161099-B1AA57FC-29A7-4274-8206-FC90B80C1A1AQ47408666-861AC38F-434C-4A21-815C-216986219B63Q47650466-E2880013-27B9-4A65-AC14-3C385D4B08ECQ47670909-5B3DA7B9-D85B-416E-911C-18E7FFD5A2D0Q47672665-98B169BB-4E29-4670-A528-1C61DFB05FBFQ48093473-132DCAD9-1876-40B1-AC5A-58227872ED96Q50044507-F9FFCDE8-797B-49BB-80D9-C9FD483E1BBCQ50239472-577BC6CB-4F5F-4405-8F78-275028E81880Q51738645-D6AFE452-CEE8-48C9-9C5A-72763520CF02Q51758674-D9F92E11-6B30-45A8-8637-717BEAD55D7BQ52315334-ED311ECD-6378-4700-9FA4-1953268A8292Q54977888-2D7A0FEC-2445-431D-8A05-88CD45081ED7Q55002611-D999A767-1582-4123-A64A-9CCC4453D373Q55325809-FCA40E38-FC34-451F-88D9-10CDC3EA04BAQ55380454-31260A52-3891-48D4-A390-789821B72AC4Q56975629-45AAAE64-BEA7-4EA5-AE8F-C66D325CC984Q57211696-A55A1F35-9149-4F99-9809-DA338C03BE6EQ58729492-96521A1C-70AE-4013-B675-3C1525AE9C0A
P2860
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The blood-brain barrier in Alzheimer's disease.
@en
type
label
The blood-brain barrier in Alzheimer's disease.
@en
prefLabel
The blood-brain barrier in Alzheimer's disease.
@en
P2860
P921
P1476
The blood-brain barrier in Alzheimer's disease
@en
P2093
Gabriela Constantin
Gennj Piacentino
P2860
P356
10.1016/J.NBD.2016.07.007
P50
P5008
P577
2016-07-15T00:00:00Z